C
The startup develops a small-molecule thyroid hormone receptor TTR stabilizer administered orally to treat peripheral and central transthyretin amyloidosis (ATTR). This drug aims to prevent the progression of severe orphan diseases by providing safe and tolerable thyroid hormone receptor stabilization.
City of New York, United States
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a small-molecule thyroid hormone receptor TTR stabilizer administered orally to treat peripheral and central transthyretin amyloidosis (ATTR). This drug aims to prevent the progression of severe orphan diseases by providing safe and tolerable thyroid hormone receptor stabilization.